These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30316896)

  • 1. Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans.
    Walton E; Yaguchi G; Keeley J; Deebajah M; Menon M; Peabody J; Dabaja A; Alanee S
    J Urol; 2019 Mar; 201(3):503-509. PubMed ID: 30316896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Contrast Enhanced Magnetic Resonance Imaging Improves Classification of Prostate Lesions: A Study of Pathological Outcomes on Targeted Prostate Biopsy.
    Druskin SC; Ward R; Purysko AS; Young A; Tosoian JJ; Ghabili K; Andreas D; Klein E; Ross AE; Macura KJ
    J Urol; 2017 Dec; 198(6):1301-1308. PubMed ID: 28709889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
    Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    Mehralivand S; Bednarova S; Shih JH; Mertan FV; Gaur S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2017 Sep; 198(3):583-590. PubMed ID: 28373133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies.
    Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Preisser F; Tilki D; Fisch M; Graefen M; Budäus L
    J Urol; 2018 Nov; 200(5):1035-1040. PubMed ID: 29935274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
    Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
    J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.
    Osses DF; van Asten JJ; Kieft GJ; Tijsterman JD
    World J Urol; 2017 Feb; 35(2):207-212. PubMed ID: 27287889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of prostate cancer using magnetic resonance imaging/ultrasonography image-fusion targeted biopsy in African-American men.
    Shin T; Smyth TB; Ukimura O; Ahmadi N; de Castro Abreu AL; Oishi M; Mimata H; Gill IS
    BJU Int; 2017 Aug; 120(2):233-238. PubMed ID: 28111879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
    Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
    Prendeville S; Gertner M; Maganti M; Pintilie M; Perlis N; Toi A; Evans AJ; Finelli A; van der Kwast TH; Ghai S
    J Urol; 2018 Jul; 200(1):104-113. PubMed ID: 29408568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer.
    Costa DN; Lotan Y; Rofsky NM; Roehrborn C; Liu A; Hornberger B; Xi Y; Francis F; Pedrosa I
    J Urol; 2016 Jan; 195(1):80-7. PubMed ID: 26192254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
    Chen F; Cen S; Palmer S
    Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.